Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: a Korean Diabetes Association and Korean Society of Nephrology consensus statement

Mostrar otras versiones (1)

Diabetes is a leading cause of end-stage renal disease. Therefore, prevention of renal dysfunction is an important treatment goal in the management of diabetes. The data of landmark cardiovascular outcome trials of sodium-glucose cotransporter-2 (SGLT2) inhibitors showed profound reno-protective eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Tae Jung, Moon, Ju-Young, Hur, Kyu Yeon, Ko, Seung Hyun, Kim, Hyun Jung, Kim, Taehee, Lee, Dong Won, Moon, Min Kyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Nephrology 2020
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530358/
https://www.ncbi.nlm.nih.gov/pubmed/32938820
http://dx.doi.org/10.23876/j.krcp.20.132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530358/
https://www.ncbi.nlm.nih.gov/pubmed/32938820
http://dx.doi.org/10.23876/j.krcp.20.132

Ejemplares similares